KSQ Therapeutics Inc. nailed down $80 million in series C money to push into the clinic oncology drug candidates generated by the company's CRISPRomics discovery engine. With the new cash, KSQ will move its first program into testing within the next 18 months, and plans to advance up to three more cancer bids into IND-enabling studies. The first candidate consists of a modified adoptive T-cell immunotherapy that has shown efficacy in animal models of PD-1 resistance.